Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $29.44, for a total transaction of $231,604.48. Following the sale, the director now directly owns 5,700 shares in the company, valued at $167,808. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Daniel Bradbury also recently made the following trade(s):
- On Monday, August 12th, Daniel Bradbury sold 7,883 shares of Castle Biosciences stock. The shares were sold at an average price of $26.65, for a total transaction of $210,081.95.
Castle Biosciences Stock Performance
CSTL traded down $1.26 during mid-day trading on Wednesday, reaching $28.75. 488,922 shares of the company traded hands, compared to its average volume of 306,237. The stock has a market capitalization of $793.70 million, a P/E ratio of -24.96 and a beta of 1.03. Castle Biosciences, Inc. has a 52-week low of $12.07 and a 52-week high of $32.53. The company has a quick ratio of 7.92, a current ratio of 8.12 and a debt-to-equity ratio of 0.02. The company’s fifty day moving average price is $28.36 and its 200-day moving average price is $24.03.
Analyst Ratings Changes
Several equities research analysts have commented on the company. Stephens reissued an “overweight” rating and issued a $37.00 target price on shares of Castle Biosciences in a report on Tuesday, August 6th. Robert W. Baird lifted their target price on shares of Castle Biosciences from $34.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, August 6th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $32.80.
View Our Latest Stock Analysis on Castle Biosciences
Institutional Investors Weigh In On Castle Biosciences
Institutional investors and hedge funds have recently bought and sold shares of the business. RiverPark Advisors LLC grew its holdings in Castle Biosciences by 362.2% during the 1st quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock valued at $63,000 after buying an additional 2,242 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Castle Biosciences by 70.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 5,297 shares of the company’s stock valued at $117,000 after acquiring an additional 2,187 shares in the last quarter. Denali Advisors LLC bought a new stake in Castle Biosciences in the 1st quarter valued at $186,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Castle Biosciences by 10.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock worth $215,000 after purchasing an additional 952 shares in the last quarter. Finally, Birchview Capital LP bought a new position in Castle Biosciences during the fourth quarter valued at approximately $216,000. 92.60% of the stock is owned by institutional investors.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Read More
- Five stocks we like better than Castle Biosciences
- Following Congress Stock Trades
- 3 Momentum Trades for October With Ample Upside Ahead
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- Want to Profit on the Downtrend? Downtrends, Explained.
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.